PYC Therapeutics Limited (ASX: PYC)
Health Care · Biotechnology · AU
AU$2.07
-3.27% today · +59.2% 1Y
PYC Therapeutics Limited (ASX: PYC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.46B and employs 37 people.
Over the last twelve months the share price has gained 59.2%, trading between 0.85 and 2.23.
Tweenvest scores PYC Therapeutics Limited across four factors: quality 33/100, value 69/100. Its strongest factor is value.
PYC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.46B
- Revenue (TTM)
- $13.71M
- P/E
- —
- EPS
- -0.09
- Dividend yield
- —
- Beta (5Y)
- 1.05
- 52-week high
- AU$2.23
- 52-week low
- AU$0.85
- Avg volume (3M)
- —
- Shares outstanding
- 983.51M
- Employees
- 37
- Next earnings
- —
About PYC Therapeutics Limited
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of novel RNA therapeutics for the treatment of genetic diseases in Australia. The company offers VP-001, a drug program, which is in Phase 1 clinical trial for the treatment of retinitis pigmentosa type 11; PYC-001, a drug candidate for treating blinding eye disease named Autosomal Dominant Optic Atrophy, which is in clinical studies; PYC-002, a drug program for the treatment of severe neurodevelopmental disorder named Phelan-McDermid Syndrome, which is in pre-clinical studies; and PYC-003 to treat autosomal dominant polycystic kidney disease, which is in early-stage clinical trials. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
- ISIN
- AU000000PYC7
- Founded
- 2001
- Listed since
- Nov 17, 2024
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.